Print
Email
Print Edition Stories
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Doug Banks: 10 Women to Watch in tech
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
Drug maker Sepracor Inc. said it is determining whether to continue the development of its most advanced candidate for the treatment of depression after a Phase 2 clinical trial returned “inconclusive” results that fell short of the company’s initial goals.
Sepracor, based in Marlborough, said the 514-person study was designed to evaluate the safety and effectiveness of its drug candidate, identified as SEP-225289, for the treatment of major depressive disorder. The company said the drug failed to result in a reduction in symptoms of depression following eight weeks of treatment. In a regulatory filing late Wednesday, Sepracor (Nasdaq: SEPR) said it is “in the process of further analysis of the dose response and secondary endpoints to determine how or if it will move forward with SEP-225289.”
Sepracor reported a profit of $515 million for fiscal 2008, on revenue of $1.3 billion.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
